Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia.

Pharmacology

Department of Medical Oncology/Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Published: March 2021

Background: Autoimmune hemolytic anemia (AIHA) might be associated with underlying hematological malignancies such as chronic lymphocytic leukemia. However, the association between AIHA and chronic myelogenous leukemia is extremely unusual.

Summary: We reviewed case reports and series of 54 patients with chronic myeloid leukemia (CML) who developed autoimmune hemolysis between 1952 and 2018. Almost all the patients were in the chronic phase and were classified into transplant and non-transplant groups. The onset of autoimmune hemolysis was earlier in the transplant group and required second- and third-line therapy to control it. The etiology of hemolysis is poorly understood but attributed in the transplant group to immune reconstitution, viral infections, or CML relapse. On the other hand, it is thought to be related in the non-transplant group to CML medications, especially interferon. Key Messages: Although AIHA is uncommon in chronic myelogenous leukemia patients, it should be in the differential diagnosis list for those who develop a sudden drop in hemoglobin without a bleeding source.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845422PMC
http://dx.doi.org/10.1159/000507295DOI Listing

Publication Analysis

Top Keywords

autoimmune hemolytic
8
hemolytic anemia
8
chronic myeloid
8
myeloid leukemia
8
chronic myelogenous
8
myelogenous leukemia
8
patients chronic
8
autoimmune hemolysis
8
transplant group
8
chronic
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!